NGB 2904_product_DataBase

Bioactivity	NGB 2904 is an orally active and selective dopamine (DA) D3 receptor antagonist. NGB 2904 can be used for the research of cocaine addiction[1].
In Vivo	NGB 2904 (0.1~5 mg/kg; i.p.) significantly loweres the break-point for cocaine self-administration behavior reinforced under progressive-ratio conditions and significantly inhibits cocaine-triggered reinstatement of drug-seeking behavior in rats extinguished from daily cocaine self-administration[1].NGB 2904 (0~10 mg/kg; i.p.) administered 30 min prior to the beginning of daily cocaine self-administration sessions has no significant effect on cocaine self-administration behavior at a unit cocaine reinforcement dose of 0.5 mg/kg/infusion compared to vehicle-treated animals. NGB 2904 (0.1 and 1 mg/kg) pretreatment significantly inhibits the enhanced brain stimulation reward produced by 2 mg/kg, but not by 10 mg/kg, of cocaine. NGB 2904 pretreatment produces a significant attenuation of this cocaine-triggered reinstatement of drug-seeking[1]. Animal Model:
Name	NGB 2904
CAS	189060-98-8
Formula	C28H29Cl2N3O
Molar Mass	494.46
Appearance	Solid
Transport	Room temperature in continental US; may vary elsewhere.
Storage	4°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Reference	[1]. Xi ZX, et al. The novel dopamine D3 receptor antagonist NGB 2904 inhibits cocaine's rewarding effects and cocaine-induced reinstatement of drug-seeking behavior in rats. Neuropsychopharmacology. 2006;31(7):1393-1405.

PeptideDB